The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1276
December 17, 2007
View Complete Issue         Table of Contents 2019 
Two Amlodipine/ARB Combinations for Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Two Amlodipine/ARB Combinations for Hypertension
December 17, 2007 (Issue: 1276)
The FDA has approved Exforge (Novartis) and Azor (Daiichi Sankyo), the first combinations of a calcium channel blocker (CCB) with an angiotensin receptor blocker (ARB) for treatment of hypertension. Amlodipine is the CCB in both products. The ARBs...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Two Amlodipine/ARB Combinations for Hypertension
Article code: 1276a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.